



February 6, 2026

To,
The Corporate Relations Department
The BSE Limited
Department of Corporate Services
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001.
Ref:- Scrip Code:- 500126

To,
The Listing Department
The National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (East),
Mumbai – 400051
Ref:- Symbol:- PGHL

Dear Sir / Madam,

Sub: Unaudited Financial Results for the quarter ended December 31, 2025

We are pleased to inform you that at a meeting of the Board of Directors of the Company held today (commenced at 12:11 p.m. and ended at 14.23 p.m.), the Unaudited Financial Results for the quarter ended December 31, 2025 were approved.

We are enclosing herewith the following:

- a. Unaudited Financial Results;
- b. Limited Review Report in respect of the Unaudited Financial Results furnished by Statutory Auditors of the Company.

Further, we are pleased to inform you that the Board of Directors of the Company at its meeting held today, inter alia, have declared an Interim Dividend for the Financial Year 2025-26 of Rs. 160 per Equity Share (including a one-time special dividend of Rs. 50 per Equity Share). The dividend shall be paid on or before March 4, 2026.

The Company has fixed the record date for the purpose of eligibility for payment of said Interim Dividend shall be February 12, 2026.

Kindly take the same on record and oblige.

Thanking you.

For **Procter & Gamble Health Limited**

Zeal Rupani
Company Secretary

PROCTER & GAMBLE HEALTH LIMITED

Regd. Office: P&G Plaza, Cardinal Gracias Road, Chakala, Andheri (E), Mumbai : 400 099.

CIN No. L99999MH1967PLC013726, email: investorgrievance.im@pg.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2025

(₹ in lakhs)

Sr. No.	Particulars	(1) Three months ended 31st December 2025 (Unaudited)	(2) Preceding Three months ended 30th September 2025 (Unaudited)	(3) Corresponding Three months ended 31st December 2024 (Unaudited)	(4) Nine months ended 31st December 2025 (Unaudited)	(5) Corresponding Nine months ended 31st December 2024 (Unaudited) (refer note 4)	(4) Previous Year (Nine Months) ended 31st March 2025 (Audited) (refer note 3)
1.	Revenue from Operations	37 386	32 492	30 977	103 752	90 706	93 417
2.	Other Income	436	495	396	1 334	937	1 035
3.	Total income (1+2)	37 822	32 987	31 373	105 086	91 643	94 452
	Expenses						
	a) Cost of materials consumed	8 447	7 813	6 160	22 214	17 719	20 059
	b) Purchases of stock-in-trade (Traded goods)	1 332	1 064	1 328	4 827	5 195	4 716
	c) Changes in inventories of finished goods,work-in-progress and stock in trade	1 203	(2 037)	85	180	1 381	1 475
	d) Employee benefits expenses	6 181	5 388	4 705	17 170	14 190	14 206
	e) Depreciation and amortisation expenses	590	608	555	1 742	1 848	1 669
	f) Finance costs	10	12	15	34	50	43
	g) Other expenses	9 177	8 237	6 356	27 254	23 649	21 122
4.	Total expenses (4)	26 940	21 085	19 204	73 421	64 032	63 290
5.	Profit before exceptional items and tax (3-4)	10 882	11 902	12 169	31 665	27 611	31 162
6.	Less: Exceptional items (refer note 7)	-	-	-	-	2 019	-
7.	Profit before tax (5-6)	10 882	11 902	12 169	31 665	25 592	31 162
8.	Tax expenses						
	a) Current Tax	2 926	3 054	2 904	8 274	6 978	7 763
	b) Deferred Tax Charge / (Credit)	(167)	(6)	175	(204)	(387)	(49)
	c) Adjustment of tax relating to earlier periods	364	-	-	364	-	7
	Total tax expenses	3 123	3 048	3 079	8 434	6 591	7 721
9.	Net Profit for the period / year (7-8)	7 759	8 854	9 090	23 231	19 001	23 441
10.	Other Comprehensive Income						
	Items that will not be reclassified to profit or loss						
	i. Re-measurement gains / (losses) on defined benefit plans	118	323	(266)	354	(377)	(350)
	ii. Income tax effect on above	(30)	(81)	67	(89)	94	88
	Other Comprehensive Income, net of tax	88	242	(199)	265	(283)	(262)
11.	Total Comprehensive Income for the period / year (9+10)	7 847	9 096	8 891	23 496	18 718	23 179
12.	Paid-up equity share capital (Face Value ₹ 10/- each)	1 660	1 660	1 660	1 660	1 660	1 660
13.	Other equity	-	-	-	-	-	52 036
14.	Earnings per equity share (of ₹ 10/- each)						
	*(not annualised)						
	(a) Basic and Diluted (in ₹) (before exceptional items)	* 46.74	* 53.34	* 54.76	* 139.95	* 126.63	141.22
	(b) Basic and Diluted (in ₹) (after exceptional items)	* 46.74	* 53.34	* 54.76	* 139.95	* 114.47	141.22

PROCTER & GAMBLE HEALTH LIMITED

Regd. Office: P&G Plaza, Cardinal Gracias Road, Chakala, Andheri (E), Mumbai : 400 099.

CIN No. L99999MH1967PLC013726, email: investor@procterandgamble.com

Notes:

1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on February 6, 2026 and have been subjected to a limited review by the Statutory Auditors of the Company. These financial results are prepared and published in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and expressed "Unmodified" Conclusion.
2. The Unaudited Financial Results are prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 and Interim Financial Reporting (Ind AS-34), as prescribed under Section 133 of the Companies Act, 2013, read with relevant Rules issued thereunder and other accounting principles generally accepted in India.
3. The Board of Directors of the Company, on January 23, 2025, approved the change of the Financial Year end from June 30th to March 31st. Accordingly, the previous Financial Year of the Company viz., 2024-25 was for a period of nine months commencing on July 1, 2024, and ending on March 31, 2025.
4. Pursuant to the change in the Financial Year as mentioned in note 3 above, the figures for the corresponding nine months ended December 31, 2024 are arrived at by adding the published audited figures for the quarter ended June 30, 2024 and the published unaudited figures for the six months ended December 31, 2024.
5. The Company has identified Pharmaceuticals as its single primary reportable segment in accordance with the requirement of Ind AS 108 - Operating Segments. Accordingly no separate segment information has been provided.
6. The Board of Directors at its meeting held on February 6, 2026 has declared for the current year an interim dividend of ₹ 160 per equity share (nominal value of ₹ 10 per equity share) (including a one-time special dividend of ₹ 50 per equity share) aggregating to ₹ 26 559 lakhs
7. During the quarter ended June 30, 2024, the Company had discontinued production of injections at its manufacturing plant in Goa effective September 30, 2023, as the Company had started to source injections portfolio of its products from a contract manufacturer. Post evaluation of various alternatives, during the quarter ended June 30, 2024, the Company had entered into an agreement for sale of the assets of its injection plant for a consideration of ₹ 790 Lakhs and impaired the balance amount of ₹ 627 Lakhs. Based on above, the company had re-evaluated the usability of assets in their capital work in progress and thereby impaired other related assets by an amount of ₹ 1 392 Lakhs. The above total amount of ₹ 2 019 Lakhs was disclosed as an exceptional item for the nine months ended December 31, 2024.
8. The unaudited financial results are available on the website of the Company (www.pghealthindia.com) and on the websites of BSE (www.bseindia.com) and NSE (www.nseindia.com).
9. Previous year's/period's figures have been regrouped/ rearranged/reclassified wherever necessary to conform to current period's classification.
10. The Government of India has consolidated 29 existing labour legislations into a unified framework comprising four labour codes viz the Code on Wages, 2019, the Code on Social Security, 2020, the Industrial Relations Code, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as the "Labour Codes"). The Labour Codes have been made effective from November 21, 2025. The Ministry of Labour & Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations. The Company has evaluated the impact of the Labour Codes on the basis of information currently available. Management has assessed that the incremental impact, if any, of these changes is not expected to be material given that the current salary structure of the Company is in line with the requirements of the Labour Codes. The Company continues to monitor the finalisation of Central / State Rules and clarifications from the Government on other aspects of the Labour Codes and would make appropriate adjustments, if needed.
11. The Company does not have a subsidiary, an associate or a joint venture as at 31st December, 2025.

Place : Mumbai
Date : February 06, 2026

For and on behalf of the Board of Directors of
Procter & Gamble Health Limited

Milind
Vasant
Thatte

Digitally signed
by Milind
Vasant Thatte
Date:
2026.02.06
13:57:24 +05'30'

Milind Thatte
Managing Director

Independent Auditor's Review Report on quarterly and year to date Unaudited Financial Results of Procter & Gamble Health Limited pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 (as amended)

To the Board of Directors

Procter & Gamble Health Limited

1. We have reviewed the accompanying Statement of Unaudited Financial Results of Procter & Gamble Health Limited ("the Company") for the quarter ended December 31, 2025 and year to date results for the period from April 01, 2025 to December 31, 2025 ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder (hereinafter referred to as "the said Indian Accounting Standard") and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of the company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the said Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. We draw attention to Note 4 to the Statement with regard to Unaudited Financial Results which includes the results for corresponding nine months ended December 31, 2024 which is arrived at by adding the

HARIBHAKTI & CO. LLP

Chartered Accountants

published audited figures for the quarter ended June 30, 2024 & published unaudited figures for the six months period ended December 31, 2024, on which we had issued a separate Limited Review Report.

Our report is not modified in respect of this / these matter(s).

For Haribhakti & Co. LLP

Chartered Accountants

ICAI Firm Registration No.103523W/W100048

SUMANT
MANGESH
SAKHARDANDE

Digitally signed by
SUMANT MANGESH
SAKHARDANDE
Date: 2026.02.06
14:15:49 +05'30'

Sumant Sakhardande

Partner

Membership No.: 034828

UDIN: 26034828LJIQCJ3717

Place: Mumbai

Date: February 06, 2026